HARMONY BIOSCIENCES

44th Annual J.P. Morgan Healthcare Conference

JEFFREY M. DAYNO, MD

January 13,2026 | San Francisco

NASDAQ LISTED HRMY

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue for WAKIX, expectations for the growth and value of WAKIX, plans to submit an NDA for pitolisant GR; plans to conduct trials, collect or receive data, or continue investigating any of our product candidates or potential indications; our plans to extend the pitolisant franchise into the 2040s; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX and, if approved, our other product candidates; the rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved; our research and development plans, including our efforts to explore the therapeutic potential of pitolisant in additional indications, including pitolisant GR and pitolisant HD; our ongoing and planned clinical trials; our ability to expand the scope of our license agreements with Bioprojet Société Civile de Recherche (“Bioprojet”); the availability of favorable insurance coverage and reimbursement for WAKIX and, if approved, our other product candidates; the timing of, and our ability to obtain, regulatory approvals for pitolisant for other indications, including pitolisant GR and pitolisant HD, as well as any other product candidates; our estimates regarding expenses, future revenue, capital requirements and additional financing needs; our ability to identify, acquire and integrate additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; statements related to our intended share repurchases and repurchase timeframe and the significant costs and required management time as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 25, 2025, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

HARMONY BIOSCIENCES

MOMENTUM

ON TRACK FOR BLOCKBUSTER STATUS



5 PHASE 3 PROGRAMS



STRONG FINANCIAL PROFILE

PITOLISANT FRANCHISE STRATEGY

HARMONY BIOSCIENCES

The Pitolisant Franchise: Grow, Extend and Expand Leadership by Addressing Unmet Patient Needs

	WAKIX®*	Pitolisant GR	Pitolisant HD
NARCOLEPSY UNMET NEEDS	100% All other FDA-approved treatments are scheduled (CII – CIV)	88% Report GI disturbances[1,2]	75% Residual symptoms[3]; 60% Report fatigue[4]
PRODUCT PROFILE	First and only non-scheduled treatment Strong efficacy in EDS, Cataplexy Established safety, tolerability Low drug-drug interactions	Gastro-resistant coating No titration; Start at therapeutic dose	Higher dose, enhanced efficacy Narcolepsy (with fatigue indication) IH (with sleep inertia indication)
STRATEGY	**GROW** *"On Track for $1B+ in Narcolepsy Alone"*	**EXTEND** *"New and previous patients"*	**EXPAND** *"New, previous, and existing patients"*

1. Barateau et al., Dauvilliers, 2019; 2. Wang et al., 2023; 3. McCullough et al. Novel treatment options in narcolepsy, Chicago Rush Memorial Center - SLEEP 2019 Abstract; 4. Droogleever et al. (2012). Severe fatigue in narcolepsy with cataplexy. Sleep, 21(2), 163-169;
* WAKIX attributes based on FDA-approved adult narcolepsy product labelling.

Extending and Expanding the Pitolisant Franchise to the Mid-2040s



- Two meaningfully differentiated product profiles building off WAKIX with anticipated PDUFA dates prior to LOE; utility patents filed to 2044
- Pursuing other indications (fatigue in narcolepsy, sleep inertia in idiopathic hypersomnia) to drive greater differentiation, patient benefit and net revenue growth
- On track to obtain pediatric exclusivity for WAKIX; additional six months of exclusivity (Q3 2030)

KEY TAKEAWAY

Advancing Differentiated Products to Strengthen Leadership Position in Sleep/Wake

HARMONY BIOSCIENCES

PITOLISANT FRANCHISE STRATEGY

HARMONY BIOSCIENCES

GROW EXTEND EXPAND

2026 Net Revenue Guidance

WAKIX Net Revenue Growth 2020–2025



1. Net Revenue for fiscal year 2025 is preliminary, unaudited and subject to change

$1.00B-1.04B

2026 NET REVENUE GUIDANCE

Wakix pitolisant tablets

On Track to Achieve $1B+ in Narcolepsy Alone

HARMONY BIOSCIENCES

WAKIX® Is One of the Most Successful Orphan/Rare Launches

Average Patients on WAKIX



People Living With Narcolepsy in the U.S.[1]



> 50% of Patients Undiagnosed

1. https://narcolepsynetwork.org/accessed Feb 2024

KEY TAKEAWAY

After Six Years of Growth, Large Market Opportunity Remains

Strong Commercial Engine Driving Continued Growth

	Strong Foundation	Recent Developments	Implication
DIFFERENTIATED PRODUCT	Only non-scheduled treatment, unique MOA	6+ years clinical experience	**Unique & Familiar**
EXPERIENCED TEAM	Many team members joined at launch	Refined call plan, promo mix, messaging	**Trusted & Credible**
BROAD PAYER ACCESS	>80% lives covered, often advantaged	New wins further expanding coverage	**Accessible**
PATIENT SUPPORT	Commercial model supports patients, enables broad data capture	Added staff, proactive triage, recontact team	**Supportive**
INVESTMENT AND EXPANSION		• **In 2026, expanding field sales, field reimbursement and remote sales teams** • **Launching online portal and more**	**Building Momentum**

PITOLISANT FRANCHISE STRATEGY

HARMONY BIOSCIENCES

GROW **EXTEND** EXPAND

Pitolisant GR: Fast-To-Market Strategy Based on Demonstration of Bioequivalence to WAKIX® Formulation

POSITIVE PIVOTAL BIOEQUIVALENCE STUDY

DOSING OPTIMIZATION STUDY COMPLETED

100% of the patients (46/46) able to initiate pitolisant GR at the therapeutic dose,17.8mg, without titration;
No new safety or tolerability issues reported

NDA SUBMISSION Q2 2026

ANTICIPATED PDUFA DATE Q1 2027

UTILITY PATENTS FILED TO EXTEND PITOLISANT FRANCHISE TO 2040s

PITOLISANT FRANCHISE STRATEGY

HARMONY BIOSCIENCES

GROW EXTEND **EXPAND**

Pitolisant HD: Enhanced Formulation, Differentiated Product Profile

2027

Phase 3 Topline Data

- **Narcolepsy (ONSTRIDE 1)**
- **IH (ONSTRIDE 2)**

ENHANCED FORMULATION WITH OPTIMIZED PK PROFILE AND HIGHER DOSE

Designed to address the need for greater efficacy in excessive daytime sleepiness (EDS) in patients with central disorders of hypersomnolence

PROGRAMS TO PURSUE A DIFFERENTIATED LABEL

Fatigue in narcolepsy; sleep inertia in IH

PHASE 3 REGISTRATIONAL TRIALS INITIATED IN Q4 2025

Topline data readouts anticipated in 2027; PDUFA dates anticipated 2028

ONSTRIDE 1
STUDY FOR PEOPLE WITH NARCOLEPSY

ONSTRIDE 2
STUDY FOR PEOPLE WITH IDIOPATHIC HYPERSOMNIA

UTILITY PATENTS FILED TO EXPAND PITOLISANT FRANCHISE INTO 2040s


Wakix®
pitolisant tablets
HARMONY
BIOSCIENCES

ROBUST PIPELINE



Innovative Late-Stage Pipeline

PRODUCT	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	REGULATORY FILING	MARKETED PRODUCT
WAKIX®	EDS in Narcolepsy (Adults)						
	Cataplexy in Narcolepsy (Adults)						
	EDS in Narcolepsy (Pediatric)						
	Prader-Willi Syndrome (PWS)						
Pitolisant	Pitolisant Gastro-Resistant (GR) in Narcolepsy (Adults)						
	Pitolisant High-Dose (HD) in Narcolepsy (Adults)						
	Pitolisant High-Dose (HD) in Idiopathic Hypersomnia (Adults)						
	Pitolisant High-Dose (HD) in Myotonic Dystrophy (DM1)						
BP1.15205 (Orexin-2 Receptor Agonist)	Sleep/Wake Disorders						
CBS105^	Treatment-Resistant Narcolepsy						
HBS-102	PWS						
EPX-100 (Clemizole Hydrochloride	Dravet Syndrome (DS)						
	Lennox-Gastaut Syndrome (LGS)						
EPX-200 (Lorcaserin)	Developmental and Epileptic Encephalopathies						
CBS104^	Refractory Epilepsy						

^Research collaboration with CiRC Biosciences.

Momentum Across the Pipeline; Multiple Catalysts 2026–2028

BP1.15205:
Potential Best-In-Class Orexin 2 Receptor (OX2R) Agonist

2026

Phase 1 Clinical PK Data Anticipated Mid-2026

PRECLINICAL DATA PRESENTATION AT SLEEP AND WSC

Single-oral dose administration of BP1.15205 in transgenic mice produced significant and dose-dependent increases in total wakefulness time and sleep latency at every dose tested beginning at 0.03 mg/kg and 0.1 mg/kg, respectfully, consistent with high potency

FIH STUDY INITIATED IN 4Q 2025

Clinical data anticipated in mid-2026

UNIQUE STRUCTURE/CHEMICAL SCAFFOLD

Differentiated from other known OX2R agonist chemical structures

CLINICAL POTENTIAL

- Potency and selectivity
- Potent on-target effects
- Potentially better AE profile
- Once-daily dosing

EPX-100: Safety and effectiveness data from ongoing OLE of the Phase 3 Dravet Syndrome (DS) study presented at AES 2025

Argus

CLINICALLY MEANINGFUL REDUCTION IN SEIZURES

Median reduction of ~50% in countable motor seizure frequency per 28 days (CMS-28) in participants who had at least 6-month exposure to EPX-100; at least 50% reduction in CMS-28 in 50% of these participants

PRODUCT PROFILE: POTENTIAL TO OFFER A UNIQUE RISK/BENEFIT PROPOSITION

No additional laboratory or special safety monitoring

BID DOSING REGIMEN

Convenient for patients and caregivers

ONGOING PHASE 3 REGISTRATIONAL TRIAL IN PATIENTS WITH DRAVET SYNDROME (Argus Study)

Topline data anticipated in 2027

HARMONY BIOSCIENCES

EPX-100: One of Most Advanced 5-HT2 (Serotonin) Agonist Programs in DEEs

LIGHTHOUSE
LGS CLINICAL STUDY

1H 2027

Anticipate Topline Data from Ongoing Global Phase 3 Trial

ESTABLISHED 5-HT2 (SEROTONIN) AGONIST MECHANISM OF ACTION

MoA validated via the zebrafish model

ONGOING PHASE 3 TRIAL IN LENNOX-GASTAUT SYNDROME (LGS) (LIGHTHOUSE Study)

Topline data anticipated 1H 2027

SAFETY: POTENTIAL TO OFFER A UNIQUE RISK/BENEFIT PROPOSITION

No additional laboratory or special safety monitoring

BID DOSING REGIMEN

Convenient for patients and caregivers

HARMONY BIOSCIENCES

Path to Long-Term Value Creation Beyond 2026

2026

Pitolisant PWS
Phase 3 TLD

OX2R
Phase 1 clinical PK data

2027

Pitolisant GR PDUFA

Pitolisant HD
Phase 3 TLD in narcolepsy and idiopathic hypersomnia (IH)

EPX-100 DS/LGS
Phase 3 TLD

2028

Pitolisant HD PDUFA
narcolepsy and IH

EPX-100 DS/LGS PDUFA

Pitolisant PWS PDUFA

KEY TAKEAWAY

Pipeline Poised to Deliver Value Through Extension and Expansion of Pitolisant Franchise and Innovative Epilepsy Assets

STRONG FINANCIAL PROFILE

Driving Value for Shareholders Based on Strong Financial Profile



1. Net Revenue for fiscal year 2025 is preliminary, unaudited and subject to change

CONSISTENT REVENUE GROWTH AND PROFITABILITY

ON TRACK TO BLOCKBUSTER STATUS IN NARCOLEPSY

SELF FUNDING ACROSS THE ENTERPRISE

POISED FOR VALUE CREATION

HARMONY BIOSCIENCES

HARMONY BIOSCIENCES

MOMENTUM

ON TRACK FOR BLOCKBUSTER STATUS



5 PHASE 3 PROGRAMS



STRONG FINANCIAL PROFILE


MOMENTUM
To deliver on our promise to patients and create value for shareholders
HARMONY
BIOSCIENCES

company/harmonybiosciences/ @harmonybio harmony_biosciences

www.harmonybiosciences.com

NASDAQ
LISTED
HRMY